Skip to main content
Delfa

← Trials/Trial dossier/NCT00105547

CompletedPhase 3

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

Lead sponsor

Myrexis Inc.

Asset

Tarenflurbil

Listed sites

132

Recruiting sites

-

Enrollment

1,600

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

•Cognition and activities of daily living

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDMPC-7869-04-005.02
NCT IDNCT00105547

Timeline

Milestones

Study start2005-02 (month precision)
Study first posted2005-03-16estimated
Study completion2008-05actual (month precision)
Last update posted2009-05-05estimated

Assets

Drug assets

Tarenflurbil

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have had a diagnosis of probable Alzheimer's disease.
•Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
•Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
•Ability to read and understand English or Spanish to ensure compliance with cognitive testing and study visit procedures.
•Female subjects must be surgically sterile or postmenopausal for > 1 year.
•Subjects currently taking approved medication for Alzheimer's disease for at least six months prior to day 1 may be enrolled.
•Subjects must have a reliable caregiver who can read, understand and speak English or Spanish

Exclusion criteria

•Current evidence of other causes of dementia.
•History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
•Chronic or acute renal, hepatic or metabolic disorder.
•Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
•Major surgery and related complications not resolved within 12 weeks prior to Day 1.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Function / daily living
1
Behavior / neuropsychiatric
1

Function / daily living

1 endpoint
Primary/protocol endpoint

Cognition and activities of daily living

Time frame:18 mos

descriptive

Behavior / neuropsychiatric

1 endpoint
Secondary/protocol endpoint

Global function and behavior

Time frame:18 mos

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.